Abstract
The molecular pathogenesis of the myeloproliferative disorders (MPD) is poorly understood, except for chronic myeloid leukemia (CML). Recently, several groups have discovered a novel recurrent unique acquired clonal mutation in a tyrosine-kinase JAK2 in patients with Philadelphia-negative MPD and other myeloid disorders. It consists in a guanineto- thymine change encoding a valine to phenylalanine at codon 617 (JAK2 V617F). JAK2 and the other members of the Janus kinase family are tyrosine kinases that function as intermediates between membrane receptors and intracellular signalling molecules. The mutation occurs within the enzymatically inactive JH2 pseudo-kinase domain that regulates the active JH1 kinase domain. The JAK2 activation leads to constitutive JAK and STAT (activators of transcription) hyperactivation with induction of growth factor hypersensitivity and cell transformation. Some authors have found a higher risk of vascular thrombosis and higher platelet activation when the mutation is present. Therefore, the JAK2 mutation offers a molecular target for new drugs investigation in a similar way to bcr/abl rearrangement in CML. For all these reasons, several studies related to JAK2 have arisen in the last year. In this report, we will review the literature and discuss its possible clinical and prognostic significance.
Keywords: Myeloproliferative diseases, JAK2
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: JAK2 as a Molecular Marker in Myeloproliferative Diseases
Volume: 5 Issue: 3
Author(s): R. Mata, D. Subira, A. Garcia-Raso and P. Llamas
Affiliation:
Keywords: Myeloproliferative diseases, JAK2
Abstract: The molecular pathogenesis of the myeloproliferative disorders (MPD) is poorly understood, except for chronic myeloid leukemia (CML). Recently, several groups have discovered a novel recurrent unique acquired clonal mutation in a tyrosine-kinase JAK2 in patients with Philadelphia-negative MPD and other myeloid disorders. It consists in a guanineto- thymine change encoding a valine to phenylalanine at codon 617 (JAK2 V617F). JAK2 and the other members of the Janus kinase family are tyrosine kinases that function as intermediates between membrane receptors and intracellular signalling molecules. The mutation occurs within the enzymatically inactive JH2 pseudo-kinase domain that regulates the active JH1 kinase domain. The JAK2 activation leads to constitutive JAK and STAT (activators of transcription) hyperactivation with induction of growth factor hypersensitivity and cell transformation. Some authors have found a higher risk of vascular thrombosis and higher platelet activation when the mutation is present. Therefore, the JAK2 mutation offers a molecular target for new drugs investigation in a similar way to bcr/abl rearrangement in CML. For all these reasons, several studies related to JAK2 have arisen in the last year. In this report, we will review the literature and discuss its possible clinical and prognostic significance.
Export Options
About this article
Cite this article as:
R. Mata , D. Subira , A. Garcia-Raso and P. Llamas , JAK2 as a Molecular Marker in Myeloproliferative Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (3) . https://dx.doi.org/10.2174/187152507781058654
DOI https://dx.doi.org/10.2174/187152507781058654 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Technologies in Male Contraception
Current Women`s Health Reviews Recent Clinical Aspects of Eating Disorders
Reviews on Recent Clinical Trials Adrenergic Action in Breast Cancer
Current Cancer Therapy Reviews New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry The Role of Endothelial Progenitor Cells and Statins in Endothelial Function: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Synthesis and Evaluation of Indole Based Molecules for Treatment of Oxidative Stress Related Diseases
Current Topics in Medicinal Chemistry Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Uric Acid and Oxidative Stress
Current Pharmaceutical Design Patenting Penicillium Strains
Recent Patents on Biotechnology Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Cholesterol Absorption Blockade with Ezetimibe
Current Drug Targets - Cardiovascular & Hematological Disorders Adjunctive Therapies in Severe Pneumonia in Critical Care Patients
Infectious Disorders - Drug Targets